Ravi Vij, MD, MBA, delves into the distinctive logistical demands of CAR T-cell therapy versus bispecific antibodies and discusses the potential impact of evolving CAR T technologies on patient accessibility in the realm of hematologic malignancies.
The advent of CAR T-cell therapies and bispecific antibodies has transformed the treatment landscape for blood cancers, with each modality presenting specific resource and staffing requisites.
In an enlightening conversation with The American Journal of Managed Care® (AJMC®), Ravi Vij, MD, MBA, a prominent figure in the Division of Medical Oncology at Washington University School of Medicine, shed light on why CAR T-cell therapy remains notably intricate to administer compared to bispecific antibodies, especially within community healthcare settings.
Moreover, Dr. Vij explored the potential benefits that newer technologies, such as allogeneic and in vivo CAR Ts, might offer in terms of accessibility and scalability. However, concerns persist regarding their efficacy, infection susceptibility, and long-term viability. While advancements in technology could enhance patient reach, effectively managing adverse events like cytokine release syndrome (CRS) and neurotoxicity remains pivotal for safe and successful implementation.
Key Differences in Resource and Staffing Requirements for CAR T vs. Bispecific Therapies:
CAR T-cell therapies pose significantly higher logistical challenges compared to bispecific antibodies, necessitating specialized facilities for T cell collection and CAR T-cell cryopreservation. The training of nursing and ancillary staff is more rigorous due to the elevated risk of severe CRS and neurotoxicity associated with CAR T therapies. Unlike bispecifics, which can potentially be administered by community physicians, CAR T therapies may pose challenges in transitioning to routine community settings due to their complexity.
Implications of Novel CAR T Technologies on Patient Access and Potential Hurdles:
The development of innovative CAR T technologies, such as allogeneic CAR Ts, holds promise in simplifying access by offering off-the-shelf solutions. However, current data suggest that these allogeneic variants may exhibit lower efficacy and heightened infection risks, particularly with aggressive lymphodepletion strategies. While allogeneic CAR Ts boast quicker availability, the management of CRS and neurotoxicity remains a crucial consideration. In vivo CAR Ts, although in early developmental stages, present a potential avenue for enhanced scalability, possibly extending to community healthcare setups, pending further research and patient tolerance assessments.
Tags: bispecifics
Read more on ajmc.com